CHMP recommends Imfinzi for Stage III nsclc
This announcement contains inside information 27 July 2018 14:00 BST Imfinzi receives positive EU CHMP opinion for locally-advanced, unresectable non-small cell lung cancer Recommended marketing authorisation for patients whose tumours express PD-L1 on ≥1% of tumour cells Imfinzi is the first immunotherapy recommended for approval for the treatment of locally-advanced, unresectable NSCLC AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the